Women are seeking care for pelvic organ prolapse in increasing numbers and a significant proportion of them will undergo a second repair for recurrence. This has initiated interest by both surgeons and industry to utilize and design prosthetic mesh materials to help augment longevity of prolapse repairs. Unfortunately, the introduction of transvaginal synthetic mesh kits for use in women was done without the benefit of level 1 data to determine its utility compared with native tissue repair. This report summarizes the potential benefit/risks of transvaginal synthetic mesh use for pelvic organ prolapse and recommendations regarding its continued use.
Introduction/Background
Pelvic organ prolapse (POP), defined as the protrusion of the vagina and pelvic organs into or beyond the vaginal introitus, can affect the anterior, posterior, and apical compartments of the vagina or a combination thereof leading to a marked impact on quality of life. National population-based estimates using validated measures, reported an overall 2.9% prevalence of symptomatic POP. 1 However, other population-based surveys have revealed prevalence estimates as high as 8%. 2, 3 In the United States, an estimated 300,000 surgical procedures are performed annually for prolapse. 4 A woman's lifetime risk for undergoing a surgical intervention for symptomatic pelvic floor disorders is approximately 11% to 19%. 5 A large percentage of the women, 6% to 29%, will require additional surgery for recurrent POP or urinary incontinence, and those who have undergone at least 2 prior prolapse procedures have reoperation rates over 50%. [6] [7] [8] Efforts to combat these high failure rates and to improve patient outcomes has led to the development and introduction of materials, including synthetic mesh, to augment gynecologic reconstructive surgical repairs. 9 In light of recent developments with the use of synthetic permanent mesh in vaginal reconstructive surgery, we will restrict the discussion to this material.
FOOD AND DRUG ADMINISTRATION (FDA) SAFETY COMMUNICATION
Although the FDA cleared the first surgical mesh product specifically designed for the surgical treatment of POP in 2001, surgical mesh in absorbable and permanent forms had been used in vaginal approaches to pelvic floor disorders for several years. Biologic grafts and synthetic mesh prostheses have been utilized in abdominal repairs for POP since the 1970s. 10 The use of vaginal mesh in gynecologic surgery increased since 2004 with the development of an estimated 100 synthetic mesh devices. However, concomitant to the increased use of vaginal synthetic mesh was an increase in adverse event reporting, specifically medical device reports, within the Manufacturer and User Device Experience (MAUDE) database. In October 2008, the FDA issued a Public Health Notification to inform physicians and patients of adverse events related to vaginal reconstructive surgical use of synthetic mesh, and to provide recommendations on how to mitigate risks and counsel patients appropriately. 10 Over the next 3 years, and for reasons that are not completely delineated, the FDA observed a 5-fold increase in the number of medical device reports associated with the use of synthetic vaginal mesh in POP surgery. Thus, in response to these reports and with the impetus to address growing concerns for patient safety, the FDA released a Safety Communication reflecting data from a systematic review of the literature addressing the safety, efficacy, and limitations of existing literature for urogynecologic surgical mesh. Because of media response as well as the depth and complexity of the impact the FDA release had on patient, physician, and manufacturing companies, several national gynecological and urological organizations released response statements to provide further guidance to this issue.
NATIONAL ORGANIZATIONAL RESPONSE TO FDA RECOMMENDATIONS
The American College of Obstetricians and Gynecologists (ACOG) echoed the FDA's charge for rigorous comparative effectiveness research as well lending support to the formation of an advisory committee, the Obstetrics and Gynecology Devices Panel. ACOG also recommended voluntary physician reporting through the MAUDE database and noted that complications of vaginal reconstructive surgery also occur with nonmesh approaches. 11 The Society of Gynecologic Surgeons (SGS) reported general agreement with the recommendations made by the FDA and highlighted that discriminant use of synthetic transvaginal mesh to augment vaginal defects should be performed by trained surgeons with experience in complex reconstructive surgery and only on patients with perceived unacceptable risk of clinical failure using other nonmesh approaches. Furthermore, SGS in parallel with the FDA, called for long-term clinical trials evaluating benefits and safety of vaginal mesh placement. 12 The American Urogynecologic Society (AUGS) responded in support as well, emphasizing that the FDA Safety Communication conclusions and recommendations should not apply to the use of synthetic mesh for the treatment of stress urinary incontinence or an abdominal approach to the repair of POP. In addition, AUGS focused on the FDA's recommendations for thorough patient informed consent as well as the imperative that surgeons performing vaginal mesh procedures undergo training specific to each procedure. 13 The Society for Female Urology and Urodynamics (SUFU) was also broadly supportive of the FDA white paper, and also noted that many of the complications of vaginal mesh surgeries also occur in nonmesh procedures. It was recommended that consideration of mesh placement be conducted on a case by case basis with informed discussion. As with ACOG and AUGS, SUFU also supported a review of the FDA 501k approval process. 14 
INDICATIONS FOR MESH IN SURGICAL TREATMENT OF POP
Historically, indications for the treatment of POP have focused on patient symptomology. Patients with bothersome symptoms related to POP including, pressure, protrusion, discomfort, as well as those with associated symptoms or impact on urinary, bowel, or sexual function are considered candidates for intervention. 15 Initial marketing of synthetic vaginal mesh was aimed at improved success rates for POP surgery and time-efficient, minimally invasive procedures. Currently, limited level 1 data exists that clearly guides indications to aid in surgical decision making for the use of synthetic transvaginal mesh augmentation in POP surgery.
Authors from the Consensus of the 2nd International Urogynecological Association's (IUGA) Grafts Roundtable reported that the use of the term ''indications'' was too strong to use regarding recommendations reported on the transvaginal mesh use at this time due to the paucity of data in the literature. A summary of potential benefits of synthetic graft use are seen in Table 1 , in an adaptation from the terminology used for recommendations from IUGA delineated as ''likely to be beneficial,'' ''possibly beneficial,'' ''unlikely to be beneficial,'' and ''not recommended.'' 16 Conditions that may be taken into consideration include those in which patients experience repetitive increases in intra-abdominal pressure (chronic bronchitis, chronic constipation, or other frequent Valsalva invoking conditions, such as heavy lifting). 17 As noted in the summary table, patients with collagen deficiency disorders, denoted as deficient fascia, may also be candidates that would have a likely benefit from transvaginal synthetic mesh repair.
The authors reported that despite the possible circumstances in which mesh use may be appropriate or provide benefit to a patient with POP, they recommend that the patient be fully counseled regarding outcomes and possible complications (discussed below). Furthermore, as other reviews have demonstrated, there is a timely call for more thorough investigation of surgical mesh use in POP repair, especially studies involving the use of control or native tissue repair arms as well as the inclusion of functional short-term and long-term outcomes with validated symptom and quality of life measures.
CONTRAINDICATIONS OF MESH IN SURGICAL TREATMENT OF POP
The authors are unaware of strong evidence-based guidelines regarding absolute contraindications for the use of vaginal mesh in the surgical treatment of POP. Several studies have demonstrated increased risk of mesh exposure and wound infections with increasing BMI. 18, 19 In addition, noted is that tissue healing may be impaired in poorly
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Smoking is associated with decreased vascularity, poor tissue healing, and increased mesh exposure. 20 One series in which patients underwent abdominal sacral colpoperineorrhaphy, tobacco users were noted to have a 4-fold risk of developing mesh erosions as compared with nonsmokers. 21 These conditions as well as several others to be considered are noted in Table 2 . Although not a contraindication, and quite often a concomitant procedure, hysterectomy at the same time as anterior vaginal wall mesh augmentation does pose a significant increased risk for mesh exposure. 22 Vaginal atrophy should also be a consideration when counseling patients for transvaginal mesh repair. The vaginal epithelium should be well estrogenized both preoperatively and postoperatively with estrogen cream if necessary. 23 An additional consideration that has been noted in the literature is that of hypersensitivity reactions to synthetic transvaginal mesh. A case-controlled study that included the histologic and immunohistochemical analysis of vaginal synthetic Synthetic Mesh Use in Prolapse Surgery 279 www.clinicalobgyn.com mesh explantations in a small population of women noted markers of humorally mediated lymphocytic reaction. 24 Although graft-versus-host reactions are not predictable, caution should be exercised in women who have had previous reactions to transvaginal mesh implantation.
COMPLICATIONS OF MESH IN SURGICAL TREATMENT OF POP
In the FDA Safety Communication it was noted that mesh-associated complications are not rare. Brill and colleagues recently summarized POP adverse events as reported from the MAUDE database (Table 3) . 10, 25 As noted in the recent ACOG Committee Opinion, compared with native tissue repair, synthetic mesh exposure/erosion or extrusion is unique and the most common complication of transvaginal mesh augmentation for POP repair. Often the terms mesh exposure and mesh extrusion are utilized interchangeably. IUGA and the International Continence Society have stated that the generic use of the term ''erosion'' does not necessarily describe all clinical scenarios and complications of synthetic transvaginal mesh implantation, and therefore have provided a new terminology and classification system for complications involving transvaginal meshes, tapes, and grafts in the female pelvic floor. Within this classification system, an exposure is defined as vaginal mesh visualized through separated epithelium, whereas a mesh extrusion is the gradual passage of mesh out of the body structure or tissue 26 (Figs. 1 and 2, respectively). Rates of mesh exposure and extrusion complications vary in the literature, as does the follow-up rates of the outcome studies from which they are obtained. Many studies report mesh ''erosion'' rates. Mesh erosions as characterized by the FDA refers to mesh coming through the vagina. The FDA notes that this complication is often called exposure or extrusion. 10 For the purposes of this review, the authors will report the complication rates as they are previously published, whether those complications are reported as erosions or more specifically as mesh exposures or extrusions.
In an update to their original systematic review in 2008, the SGS analyzed 110 studies reporting adverse events associated with vaginal mesh applications in POP surgery and revealed an overall erosion rate of 10.3%. 27 Sixteen of the 110 studies reported on wound granulation tissue development and reported an overall rate of 7.8%. Rardin and Washington recently reported transvaginal mesh erosion rates varying from 0% to 25%. 28 Exposure rates for level 1 studies range from 5% to 19%. 29 A more recent review of over 1508 prolapse repair procedures using implanted prostheses, revealed a 3% reoperation rate for vaginal mesh erosion in 29 of the 858 procedures performed using transvaginal synthetic mesh. Compared with the posterior and apical compartment, mesh erosions, requiring surgical excision, were more commonly seen after anterior compartment transvaginal mesh repairs. 30 Erosions may be the most common complication reported in the MAUDE database, however, another unique complication that is often associated with pelvic pain, and perhaps a more morbid sequelae, is mesh contraction, a shrinkage or reduction in the size of the vaginal mesh implant that may lead to mesh prominences or strictures within the vagina. 31 A recent case series reported results of 17 women undergoing surgical intervention for mesh contraction. All of these women presented with severe vaginal pain and focal tenderness over the contracted portions of the mesh. Furthermore, 7 of the 17 women were noted to have vaginal tightness, and 5 of the 17 women reported vaginal shortening. All of the sexually active women within the series reported dyspareunia. 32 Moore and Miklos 23 discuss the importance of avoiding tension on the levator ani muscle and ligamentous attachments as well as minimizing vaginal epithelium excision and maximizing vaginal estrogen both preoperatively and postoperatively. Ideal graft augmentation and the avoidance of tensioning can still be complicated by scar tissue formation, which may vary from patient to patient. This complication needs to be more robustly characterized and collected in all studies reporting outcomes with synthetic transvaginal mesh augmented prolapse repairs.
DYSPAREUNIA AND VAGINAL PAIN
Weber et al 32 reported a dyspareunia rate of 19% after traditional reconstructive Synthetic Mesh Use in Prolapse Surgery 281 vaginal surgery for prolapse or incontinence. Dyspareunia rates were reported in 70 of the 110 studies from the SGS review of mesh augmented vaginal repairs with an overall rate of 9.1%. 27 Another prospective observational study reported a 20% dyspareunia rate after transvaginal synthetic mesh augmentation. 33 As revealed in a recent review of transvaginal synthetic mesh applications for prolapse repair, reported complications of dyspareunia vary from one end of the spectrum to the other. 28 In fact, Nieminen and colleagues reported a reduction in dyspareunia for patients undergoing transvaginal synthetic mesh anterior wall repairs as compared with traditional anterior repair. Ninety-seven patients were treated with anterior colporrhaphy and 105 were randomized to synthetic transvaginal mesh. The dyspareunia score was lower in the mesh group (P = 0.015). 34 Sentilhes et al 35 reported no effect of transvaginal synthetic mesh augmentation on sexual function. As noted in IUGA Grafts Roundtable, postoperative vaginal and pelvic pain after either transvaginal mesh or native tissue repairs for POP is difficult to characterize. 16 In a recent review of 23 patients undergoing transvaginal removal of synthetic mesh for mesh-related complications, vaginal pain and dyspareunia were the most noted complications. Excision of synthetic mesh resolved pain in 10 of the 11 patients. 36 
OTHER COMPLICATIONS
Seven deaths were reported to the MAUDE database for patients who underwent POP repair procedures with transvaginal mesh. Three of the deaths were related directly to the mesh placement procedure and included 2 bowel perforations and 1 hemorrhage. 37 Other major complications have been reported in the literature including retrovesical hematoma formation as well as mesh erosions not simply through the vaginal epithelium but into the bladder. 38 In addition, vesicovaginal fistula formation after the use of synthetic transvaginal mesh in the anterior compartment has been reported. 39 It is clear that a wide spectrum of complications exists for the use of transvaginal mesh in POP surgery. A thorough understanding of these complications, especially with the perspective of complications associated with native tissue repairs, and the subsequent 
282
Ellington and Richter www.clinicalobgyn.com management of them is imperative to the consideration of synthetic transvaginal mesh use in POP surgery.
MANAGEMENT OF MESH COMPLICATIONS
The majority of mesh complications can be managed conservatively. Some investigators have reported if large bore polypropylene mesh is used, the graft is typically not infected and usually does not have to be completely excised. 23 In the case of mesh extrusions and exposures, many will heal with the use of vaginal antibiotics and/or the use of vaginal estrogen cream. Other outpatient management includes the use of local anesthetic and excision of the exposed mesh. 23 Conservative treatments for dyspareunia have also included the application of vaginal estrogen cream. 40 Additional techniques to address postoperative dyspareunia include trigger point injections with antiinflammatory medications as well as the use of pelvic floor physical therapy. Dyspareunia associated with focal contracture bands or vaginal prominences has been noted to be substantially reduced with surgical excision or release when conservative measures do not alleviate symptoms. 31 
CLINICAL CORRELATION WITH COMPLICATIONS

Anterior Compartment
The historical focus of the use of transvaginal mesh has been to improve anatomic outcomes and improve POP recurrence rates as compared with traditional vaginal repairs for POP. A systematic review reported in 2008 that compared with native tissue repair, nonabsorbable synthetic mesh may improve anatomic outcomes of anterior vaginal wall repair, but there are increased risks of adverse events. 41 In one of the reviewed studies, the mesh group was reported to have a lower POP recurrence rate (6.7% compared with 38.5%), however, this was offset by a mesh exposure rate of 17.3%. 42 In a 2010 Cochrane review, higher rates of complications associated with vaginal mesh were reported as compared with native tissue anterior vaginal repairs with a reported mesh erosion rate of 10%. 43 In 2008, Jia et al 44 demonstrated lower objective failure rates for nonabsorbable synthetic vaginal mesh in comparison with xenografts, absorbable synthetic mesh, and no mesh, but mesh erosion rates were highest in the nonabsorbable group (10.2% for nonabsorbable synthetic vs. 6.0% for xenografts and 0.7% for absorbable synthetic mesh). As this was a systematic review, success was variably defined; however, the primary outcomes for efficacy were subjective prolapse symptoms as well as objective measures using both pelvic organ prolapse quantification (POP-Q) and the Baden-Walker systems.
In a more recent randomized controlled trial of 99 women with stage Z2 anterior prolapse assigned to 1 of 3 groups: anterior colporrhaphy, paravaginal repair with porcine dermis, or polypropylene mesh, Menefee and colleagues reported that vaginal paravaginal repair with polypropylene mesh had the lowest anatomic failure rate at 2-year follow-up. The anatomic failure rate, defined as POP-Q stage Z2, was 18% for the polypropylene mesh group as compared with 58% and 46% for the anterior colporrhaphy and porcine dermis groups, respectively. However, as with earlier trials the anatomic benefit, 4% recurrence rate of prolapse for synthetic vaginal mesh augmentation as compared with 13% for colporrhaphy and 12% for porcine dermis, is associated with an erosion rate of 14%. 45 Another large randomized trial reported outcomes from 389 women assigned to anterior synthetic transvaginal mesh or anterior colporrhaphy revealed a 
Apical Compartment
In comparison with the transvaginal mesh use in the anterior compartment, abdominal sacrocolpopexy is widely regarded as the gold standard for apical prolapse with success rates reported from 58% to 100% depending on outcome definitions. 47 In 2009, a systematic review of 30 studies evaluating a total of 2653 patients undergoing apical repairs with mesh kits reported success rates from 87% to 95%, though outcome definitions varied widely. 48 Abdominal apical repairs with synthetic mesh seem to have lower erosion rates than synthetic transvaginally placed mesh. In 2004, Nygaard et al 49 reported synthetic mesh erosion rates from 0.5% to 5.0% with an average erosion rate of 3.4%. The time from surgery in this review ranged from 6 months to 3 years. In a more recent systematic review, it was concluded that when comparing traditional vaginal surgery for apical prolapse to sacral colpopexy, and vaginal synthetic mesh kits, total reoperation rate was highest in the synthetic mesh kit group (8.5%), though vaginal synthetic mesh kits had a lower reoperation rate for prolapse recurrence. Complications were highest in the vaginal synthetic mesh group with a mesh erosion rate of 5.8%. 50
Posterior Compartment
Currently, there are no robust comparative studies of posterior colporrhaphy comparing nonabsorbable synthetic graft augmentation repair for posterior compartment defects to extract data regarding complications. Two retrospective case series report high success rates of 95% and 100%, respectively. The first was a series of 22 women, 14 underwent vaginal synthetic mesh repair of posterior compartment defects and 8 received a combination of polyglactin and polypropylene mesh, where success was measured by subjective outcomes. 51 The other report was a series of 31 women who underwent posterior colporrhaphy with absorbable mesh placement. One hundred percent anatomic cure rate defined as stage <2 prolapse, as defined by the ICS pelvic organ prolapse grading system, was reported at 17 months postoperatively; however, mesh erosion was noted in 6.5% of patients. 33 Despite noted factors where one may consider transvaginal mesh augmentation of vaginal prolapse, outcomes compared with native tissue repair are, in general, short term, not significantly different subjectively, and potential complications are higher although comparator groups are not always available.
Multicompartment
Few studies address multicompartment defects with comparison of vaginal synthetic mesh augmented to traditional native tissue repairs. Iglesia et al 52 and Withagen et al 53 each performed randomized controlled trials that included patients with multicompartment defects and neither study revealed improvement in success. In the trial of Iglesia and colleagues, 65 women with POP-Q stages 2 to 4 were randomized to colpopexy with synthetic mesh or traditional vaginal colpopexy. Thirty-three women were randomized to vaginal synthetic mesh colpopexy (24 anterior mesh and 8 total mesh) and 32 were randomized to traditional repair. The study ultimately was halted due to predetermined criteria for vaginal synthetic mesh erosion. The authors reported a 15.6% rate of vaginal erosions. Three months postoperatively, the subjective cure of bulge symptoms was 93.3% in the synthetic mesh arm and 100% in the traditional arm. The second study aimed to compare efficacy and safety of trocar-guided vaginal synthetic mesh with traditional vaginal repair in a population of patients with recurrent prolapse. 53 Ninety-seven women underwent traditional colporrhaphy and 93 underwent synthetic mesh repair. Although subjective improvement was comparable between the 2 groups (80% and 81%, respectively), anatomic failure at 12 months, defined as POP-Q stage Z2, was noted to be 45.2% in the traditional arm and 9.6% in the mesh arm. 52, 53 The debate that continues to develop for the care of patients with multicompartment defects, and especially those with recurrent POP, centers around whether to approach repairs vaginally with native tissue, or with transvaginal synthetic mesh, or to proceed endoscopically with laparoscopic sacrocolpopexy. Schmid and colleagues recently reported a prospective case series in which 16 women underwent laparoscopic sacrocolpopexy for treatment of recurrent POP after trocar-guided transvaginal synthetic mesh repairs. After a mean follow-up of 12 months, all of the patients reported resolution of awareness of prolapse and were found to have stage <2 on POP-Q examination. 54 Iglesia et al 55 published a case-base debate regarding appropriate surgical approach toward a patient with recurrent POP after native tissue repair and uterosacral ligament suspension. Regarding the laparoscopic approach, only 1 level 1 study was cited, a randomized controlled trial of women with stage Z2 vaginal vault prolapse, in which 53 patients were allocated to the laparoscopic sacral colpopexy arm and 55 underwent total transvaginal mesh augmentation. The primary outcome was objective success rates using POP-Q examination. At 2-year follow-up, the total objective success rate at all vaginal sites was 77% for the endoscopic arm and 43% for the total vaginal mesh arm (P<0.001), and notably, the reoperation rate was significantly higher after total vaginal mesh than laparoscopic approach (22% vs. 5%, P = 0.006). 56 The counter-argument tends to focus on complications related to longer operating room times associated with endoscopic surgery as well as cost comparisons. Regarding outcomes and complication rates between the 2 approaches, many of the differences are clouded variations of surgeon technique. 53 Furthermore, although serious endoscopic complications, such as bowel obstruction and lumbosacral osteomyelitis are low, the morbidity associated with these complications overshadows transvaginal complications of exposure and extrusion. 57
Conclusions
Undoubtedly, the primary focus of gynecologists/urogynecologists performing vaginal repairs is patient safety and optimizing outcomes. Maximizing patients' outcomes and minimizing complications is at the heart of the FDA's investigations as well the forward momentum in research efforts in this arena. A summary of the FDA's recommendations for health care providers is shown in Table 4 . The ACOG and the AUGS collaborated in an ACOG Committee Opinion release entitled Vaginal Placement of Synthetic Mesh for Pelvic Organ Prolapse, released in December 2011. The Committee Opinion sought to address several concerns including the existing outcome data for the vaginal mesh placement for POP as well as a review of the complications of vaginal mesh surgery. A summary of the recommendations from this joint committee is shown in Table 5 . 57 Physicians need to continue to review the literature, report their own outcomes, and educate patients regarding new outcome data, complications, and recommendations from national organizations in women's health regarding prolapse repair. Surgeons with specialized training in native tissue and use of synthetic mesh augmented repairs and management of complications inherent in both groups should be at the forefront of delivering care to women affected by POP.
